A Prescription for Getting Started in ABM: Recommendations for B2B Life Science Companies

Every conversation about ABM eventually arrives at the same question: where do we actually begin?

The preceding posts in this series have covered the strategic foundations, the mechanics, the tools, and the life-science-specific adaptations that make ABM work in this sector. If you’ve followed the series, you now have a clear picture of what a mature, well-executed ABM program looks like. What this post addresses is the gap between that picture and where most organizations are today - and how to close it systematically, without overreaching in the early stages or underinvesting where it matters most.

While ABM does require technology and thoughtful campaign planning, more than anything getting started requires an overall commercial strategic decision and commitment to the principles of ABM. The organizations that build effective ABM programs aren’t always the ones with the largest budgets or the most sophisticated platforms. They’re the ones that approach the program with clarity about what they are trying to achieve, honesty about what they are ready to execute, and the discipline to build incrementally rather than trying to deploy the full program on day one.

Step One: Honest Readiness Assessment

The first recommendation is one that not enough ABM vendors and consultants make explicitly: not every organization is ready to run an effective ABM program, and launching before the foundational conditions are in place will produce disappointing results that unfairly discredit the approach.

The primary characteristics of a commercial organization that most heavily influence the success of an ABM launch include:

Commercial alignment between marketing and sales. ABM requires that marketing and the commercial team agree on a shared set of target accounts, a shared definition of what constitutes a qualified account, and a clear process for what happens when a target account reaches that threshold. If marketing and sales are operating from different account lists, or if there is no agreed handoff process, adding ABM infrastructure can end up surfacing accounts that the sales team is uninformed about or uninterested in acting on.

A documented ICP. As discussed in Post 2 on building an ABM-aligned ICP, ABM targeting is only as strong as the account intelligence that underlies it. If your organization doesn’t have a clearly documented, data-grounded ideal customer profile, that is the first deliverable to produce before any ABM campaign launches. An ICP built from revenue data and commercial team input, segmented where appropriate, and tiered by account potential is the foundation on which everything else is built.

A functional CRM with clean contact data. ABM generates and depends on contact-level engagement data. That data needs to flow into a CRM that is actively maintained and used by the commercial team. A CRM that is incomplete, infrequently updated, or not integrated into the SDR or BD team's daily workflow creates a bottleneck between marketing engagement signals and commercial action.

Deal sizes that support the investment. ABM is not efficient for low-value, high-volume transactional sales. As a general guide, organizations whose average contract value is below $50,000 should carefully evaluate whether the investment in ABM is justified relative to investment in other marketing approaches. For companies whose deals regularly exceed $100,000, and particularly those with deals in the $500,000 to multi-million-dollar range, ABM's focus and precision can generate returns exceeding other approaches, or unlock opportunities that otherwise would be unavailable.

Foundational digital marketing in place. ABM works alongside other digital marketing programs, not instead of them. Organizations that have not yet built basic paid search, organic search, or content marketing capabilities are often better served by investing in those foundations first. ABM's effectiveness is amplified when there is an established content library to deploy, organic web traffic to analyze for first-party intent signals, and a functional lead nurture capability to absorb the contacts the program generates.

If these conditions are in place (or mostly in place), the program is ready to begin. If several are missing, the most valuable first investment is closing those gaps rather than launching a campaign that will underperform because the foundation isn’t ready to support it.

Step Two: Define Your ICP Segment and Build the Account List

Once the readiness conditions are confirmed, the first substantive program decision is choosing the specific ICP segment that will anchor an initial campaign.

This is a consequential choice, because the segment selection determines the relevance of every subsequent element: the account list, the persona map, the content, the messaging, and the campaign creative. Everything downstream is based on this.

In B2B life sciences, a well-defined starting segment is typically organized around a specific type of development program, clinical context, or scientific challenge rather than a broad industry category. Examples that work well as initial ABM segments include ‘companies running cell therapy clinical programs’, ‘organizations conducting rare disease trials’, ‘companies advancing Phase 1 assets into first-in-human studies’, or ‘programs requiring analysis of solid tumor samples’. The more precisely the segment is defined, the more specifically the program can speak to the shared challenges, priorities, and purchasing needs of the accounts within it.

With the segment defined, building the target list for the program can be done in two ways: If the universe of target accounts aligning to a broad ICP has already been pulled, then you can pull the accounts from that list that fit the target campaign segment. If a broad ICP universe of accounts doesn’t exist, then use your ICP and campaign segment criteria to query a life science-specific account database and find accounts aligning to the ICP and segment specifics. Ensure you are using recent data around relevant signals: regulatory filings, planned trials, funding events, announcements, etc. to find the accounts with activity that best suggests near-term purchasing needs. A starting list of 20-100 accounts is typically the right scope for an initial One-to-Few program: large enough to generate meaningful engagement data, focused enough to ensure that the marketing messages and content that form the campaign will still feel highly relevant to the audience.

Step Three: Identify the Key Personas and Their Specific Needs

With the account list in place, the next step is identifying the two or three persona groups that constitute the core buying committee for this segment. The goal is to broadly frame, based on commercial insight, the key types of people who need to be reached, and what each of them needs to see to move toward a purchasing decision.

For each persona group, the program needs to answer three questions. 1. What is the most pressing professional challenge this person is navigating in the context of the target segment? 2. What kind of content and evidence will they find credible and useful? 3. What does a positive vendor interaction look like from their perspective?

In a cell therapy program, for example, the scientific persona is likely navigating assay development or analytical method challenges specific to the modality; the program lead is focused on timeline reliability and the ability to scale with the program; the procurement persona is evaluating vendor quality systems and regulatory credentials. The same general buyer roles appear across segments, but the specific concerns, the specific language, and the specific evidence that resonates are different for each segment. Delivering messaging and value propositions based on that specificity, to the right people, is what a well-constructed One-to-Few ABM program does.

These persona profiles inform every content and messaging decision downstream, and are most effectively used as a working tool that is actively referenced throughout the campaign planning process.

Step Four: Build the Technology Foundation

Before the campaign launches, the technology infrastructure needs to be in place to run it, track it, and act on what it produces.

The minimum viable tech stack for an initial B2B life sciences ABM program includes a CRM (Salesforce and HubSpot are the most common in this sector), a marketing automation platform for email nurture and lead management, a LinkedIn advertising account for persona-level paid social, and a programmatic advertising platform capable of account-level targeting. (Note: some companies launch an “ABM-lite” approach that does not require this full tech stack - often using just segmented emails, or LinkedIn, or a combination of the two.) For organizations ready to begin measuring individual-level engagement, a contact-level advertising platform adds significant precision, though it isn't a requirement for a first program, and is often best added as a second phase.

ABM-specific platforms — tools like 6Sense, Demandbase, or Propensity — run programmatic account-level advertising, and also add account scoring, intent data aggregation, customized account elevation workflows, and can provide automated sales alerts. These platforms meaningfully improve a program's ability to prioritize accounts and trigger timely commercial action, and are worth evaluating as part of the initial build even if full deployment happens in a subsequent phase.

The integration between these tools matters as much as the tools themselves. Engagement data from advertising platforms needs to flow into the CRM so the SDR and BD teams can see account activity in context. Lead and account scoring needs to be connected to sales team task assignment, and scoring alerts need to reach sales quickly. A stack that is technically capable but not properly integrated produces data that sits in silos rather than driving action. That’s a version of the same failure mode that ABM is designed to solve.

Step Five: Create the Campaign Landing Page and Content

The core campaign destination for a One-to-Few ABM program is a landing page, or a small set of landing page variants, built specifically for the target segment. A campaign landing page should not be a generic capabilities page. For maximum effectiveness it is a page (or a few persona-specific pages) that speaks directly to the challenges of the defined segment in the specific language those personas use, with messaging and evidence calibrated to each persona's concerns.

A common approach is to build a single landing page with sections organized by persona: a section that speaks to the scientific or clinical end-user's technical challenges, a section that addresses the program lead's execution and timeline concerns, and a section that gives the procurement persona the vendor qualification information they need. A visitor who lands on the page finds content that speaks to their specific role without having to navigate away or search for it.

An alternative approach, particularly for programs with strong creative and content resources, is to build two or three persona-specific landing page variants and direct each persona to the version most relevant to their role. LinkedIn ads targeted to scientific personas link to the scientific variant; ads targeted to operational personas link to the operational variant. Both approaches work; the choice depends on available resources and the degree of differentiation in the concerns of each persona.

The landing page should include a bottom-of-the-funnel (BOFU) CTA and conversion form (contact form, demo request, consultation offer) and a gated content offer can capture leads from people who may not yet be ready for a BOFU offer. Having both types of conversion options provides routes to capture information from people actively in-market for a solution as well as those not yet ready to talk directly.

Alongside the landing page, the campaign needs persona-specific (often LinkedIn) and programmatic (segment-level) ad creative, an email nurture sequence for leads who convert on the gated asset, and an SDR outreach sequence for leads from target accounts who reach the scoring threshold. It’s also helpful to have additional assets that can be included in the nurture sequence or for use by the SDR team. These elements should be built and reviewed before the campaign goes live, not developed in parallel with a running campaign.

Step Six: Deploy, Measure, Assess, and Determine Next Steps

With the account list, persona map, tech stack, and content assets in place, the campaign launches. And for a first campaign, launch is where the real learning begins: discovering what works in this segment, for this specific commercial organization.

The metrics that matter in the first ninety days are leading indicators, not pipeline and revenue. Given life science sales cycle lengths, judging an early ABM program by revenue outcomes is likely to lead to the wrong conclusions about a program that is actually working. The metrics that reveal whether the system is functioning as intended are: the proportion of the target account list showing any engagement, lead volume from target accounts versus non-target accounts, persona coverage across the account list, SDR follow-up rate and response rate on flagged accounts, and the rate at which engaged accounts are progressing through account scoring tiers.

At the sixty to ninety day mark, a structured program review should assess these metrics honestly and draw forward-looking conclusions. Which segment or persona is generating the strongest engagement? Often, a campaign will launch with multiple value propositions in ad creative. Which messaging is driving the most interest and engagement? Which accounts are showing multi-persona engagement signals that warrant immediate tier elevation or SDR prioritization? How well are people engaging on the landing page? Is the gated content offering driving form fills?

The answers to these questions determine the next phase of the program. An initial campaign and segment that is generating strong engagement and has identified contacts with the right personas is ready for expansion: a deeper content library, a webinar to amplify the signal, and potentially the addition of contact-level targeting to refine the buying group picture at the highest-priority accounts. A segment that is generating weak engagement despite reaching the right accounts is a signal that the messaging, the content offer, or the persona map needs adjustment before the program is extended.

This review and adjustment cycle isn’t a sign that the program is failing. Just like with any digital marketing, ABM should be looked at as a “test-and-assess” process. The organizations that treat the first program phase as a learning investment, with a defined review cadence and a willingness to adjust based on data, are much more likely to have long-term success not just in an initial campaign, but with their ABM program as a whole.

Setting Internal Expectations Correctly

No prescription for getting started in ABM would be complete without a direct discussion of internal expectation management. When ABM programs are discontinued prematurely it’s often not because they’re failing, but because the organization expected faster commercial outcomes than the program structure and its own sales cycle length could deliver. 

The organizations that are most likely to see strong long-term return from ABM are those that align internally on a twelve-month horizon for meaningful pipeline metrics, maintain the program consistently through that period rather than interrupting it to chase short-term alternatives, and invest in continuous optimization rather than treating the initial program design as fixed.

ABM is a commercial capability rather than a campaign - one that improves over time as the program accumulates intelligence about a target market and an organization’s own internal functioning. This intelligence helps refine target and contacts lists, optimize content performance, and builds the commercial team's familiarity with ABM processes and how to make the best use of what the campaign is delivering. The organizations that understand this and build internal support for a program timeline that reflects it are the ones that arrive at month twelve with a genuinely transformed commercial motion and a pipeline that reflects it.

In summary: to set yourself up for ABM success, first assess readiness honestly, define the segment precisely, know your personas deeply, build the infrastructure before you need it, create content that earns engagement from the right people, and give the program the time it needs to demonstrate what it is capable of. Followed with discipline, this approach gives you a real opportunity to build a marketing program that improves as it runs, and generates real pipeline and return on investment for your organization.

‍